Details for Patent: 11,654,106
✉ Email this page to a colleague
Which drugs does patent 11,654,106 protect, and when does it expire?
Patent 11,654,106 protects ATORVALIQ and is included in one NDA.
This patent has two patent family members in two countries.
Drugs Protected by US Patent 11,654,106
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | AS AN ADJUNCT TO DIET TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ⤷ Subscribe | |||
| Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | AS AN ADJUNCT TO OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE IF SUCH TREATMENTS ARE UNAVAILABLE, TO REDUCE LDL-C IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,654,106
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3468606 | ⤷ Subscribe | |||
| World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
